CMS announced the 15 drugs selected for the third cycle of Medicare drug price negotiations for 2026, marking the first time the program includes Part B drugs. The selection expands the scope of Medicare price negotiation beyond earlier rounds that focused on Part D products. The announcement signals continued implementation of the negotiation program and identifies the products that will move into the next phase of the pricing process.
